Cardiovascular Health of Transgender Individuals During the Gender-affirming Pathway

NCT ID: NCT07187947

Last Updated: 2025-09-23

Basic Information

• Recruitment Status: RECRUITING
• Total Enrollment: 500 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2025-07-18
• Study Completion Date: 2035-12-31

Brief Summary

Gender incongruence, now classified in ICD-11 as a "marked and persistent incongruence between an individual's experienced gender and the gender assigned at birth," is managed in dedicated, multidisciplinary centres that coordinate psychological support with medical-surgical care.

Gender-affirming hormone therapy (GAHT) is central to this care pathway. In particular, masculinising GAHT for people assigned female at birth (AFAB) relies mainly on testosterone, and feminising or demasculinising GAHT for people assigned male at birth (AMAB) combines oestradiol with androgen-lowering agents such as cyproterone acetate or GnRH analogues (triptorelin, leuprorelin). In addition, Gender-affirming surgery (GAS) offers further individualised options: "Top" procedures- chest masculinisation for AFAB or breast augmentation for AMAB, and "Bottom" procedures** such as hysterectomy with or without oophorectomy, phalloplasty or metoidioplasty for AFAB; orchiectomy or vaginoplasty for AMAB. Other ancillary interventions include facial feminisation or voice surgery.

GAHT aims to suppress endogenous sex-hormone levels and secondary sex characteristics while inducing those consistent with the affirmed gender. Despite its widespread use, cardiovascular (CV) safety data are scant and largely observational. Sex-steroid receptors are ubiquitous in the vasculature and contribute to the sex-dimorphic patterns of CV risk seen in cisgender populations; GAHT is therefore biologically plausible as a modifier of CV outcomes in transgender people, yet robust evidence remains limited.

Current literature suggests that AFAB individuals on testosterone exhibit an up to 2.66-fold higher composite CV risk than cisgender AFAB comparators. The most consistent changes are higher blood pressure and lower HDL cholesterol; clinically significant polycythaemia is uncommon and treatable. Instead, AMAB individuals on feminising therapy do not show a clearly increased overall CV risk compared with cisgender AMAB peers, though data are inconsistent. An observational study reported that within four months of GAHT initiation, systolic blood pressure rose by 2.6 mmHg in trans men and fell by 4 mmHg in trans women, with no diastolic change in either group.

The current evidence base is weakened by small cohorts, inadequate control groups, and reliance on surrogate biochemical markers rather than hard clinical endpoints. Many studies also overlook GAHT exposure altogether, hampering meaningful interpretation. Moreover, social determinants-mental-health burden, substance use, and healthcare inequities-compound CV risk but are seldom accounted for.

Key unanswered questions include the long-term CV effects of GAHT, age-specific interactions with blood pressure and lipids, optimal therapeutic targets, and underlying mechanisms. Addressing these gaps demands rigorously designed, large-scale, prospective studies that actively involve transgender participants.

In summary, while GAHT is indispensable for gender affirmation, its cardiovascular implications-especially for AFAB individuals-warrant caution and systematic monitoring. Future evidence should inform tailored protocols that balance gender-affirming benefits against potential CV risks and integrate biomedical parameters with the broader social context impacting transgender health.

Detailed Description

Gender incongruence, described in the eleventh revision of the International Classification of Diseases (ICD-11) as "a marked and persistent incongruence between an individual's experienced gender and the gender assigned at birth" , is usually managed in specialised, multidisciplinary centres where psychologists, endocrinologists, gynaecologists, urologists and other professionals guide each person through the process of gender affirmation. Central to this pathway is gender-affirming hormone therapy (GAHT). In individuals assigned female at birth (AFAB) who seek masculinisation, treatment relies primarily on testosterone, whereas in those assigned male at birth (AMAB) who desire feminisation or demasculinisation, androgen-lowering agents such as cyproterone acetate or gonadotropin-releasing-hormone analogues (triptorelin or leuprorelin acetate) are combined with oestradiol; when complete feminisation is requested, suppression of endogenous testosterone and administration of oestradiol proceed in tandem. Gender-affirming surgery (GAS) offers further individualised possibilities: chest masculinisation in AFAB people and breast augmentation in AMAB people, orchiectomy or vaginoplasty for AMAB individuals, and hysterectomy with or without salpingo-oophorectomy followed by phalloplasty or metoidioplasty for AFAB individuals. Ancillary procedures, including facial feminisation and thyroplasty, may refine the outcome for AMAB clients.

The physiological goal of GAHT is to suppress endogenous sex-hormone levels and associated secondary sexual characteristics of the birth sex while inducing and maintaining hormone levels, and thus features, congruent with the individual's affirmed gender. Although GAHT is widely used, robust data on its cardiovascular safety remain scarce. Sex-steroid receptors are ubiquitous in vascular tissues and help explain the sex-specific patterns of cardiovascular (CV) risk seen in cisgender populations; accordingly, GAHT is biologically plausible as a modulator of CV outcomes in transgender people, yet the evidence base is still limited. Current literature points to an increased composite CV risk-up to 2.66-fold-among AFAB individuals receiving testosterone compared with cisgender AFAB controls. The most frequently reported risk-factor shifts in this group include higher blood pressure and lower high-density lipoprotein cholesterol, whereas clinically significant polycythaemia remains uncommon and treatable. By contrast, studies have not shown a statistically significant overall CV risk elevation in AMAB individuals treated with feminising regimens when compared with cisgender AMAB peers, though findings are inconsistent. One observational investigation documented that within four months of starting GAHT systolic blood pressure rose by 2.6 mmHg in trans men but fell by 4 mmHg in trans women, with diastolic values remaining unchanged in both cohorts.

Interpretation of these data is hindered by small sample sizes, the paucity of large prospective cohorts, inadequate control populations and the predominance of surrogate biochemical markers in place of clinical CV end-points. Moreover, several published studies neglect to register GAHT exposure, despite its fundamental role in transgender health management, underscoring the need for further research into the therapy's effects and risks. Social determinants of health compound the picture: higher prevalences of mental-health disorders, substance misuse and structural healthcare inequities are increasingly recognised in transgender communities and likely contribute to the observed CV risk burden.

Many critical questions therefore remain unanswered. The long-term impact of GAHT on cardiovascular morbidity and mortality is unknown, as is the extent to which a person's age modifies GAHT-related shifts in blood pressure, lipid profile or other risk parameters. Clinicians lack evidence-based targets for blood pressure or surrogate CV markers in trans men and trans women, and the biological mechanisms that underlie GAHT-related alterations in CV risk factors are not fully understood. Addressing these uncertainties will demand rigorously designed, large-scale prospective studies, conducted with active involvement of transgender participants, that integrate biomedical outcomes with the broader social realities shaping transgender health.

In summary, although GAHT is indispensable for many individuals seeking gender affirmation, its cardiovascular implications-particularly the elevated risk signalled in AFAB people receiving testosterone-warrant cautious, evidence-based monitoring. Future work should clarify long-term outcomes, refine management protocols and ensure that clinical guidelines reflect both the physiological effects of hormone therapy and the social determinants that influence cardiovascular health in transgender populations.

Conditions

Gender Incongruence; Cardiovascular (CV) Risk; Cardiovascular Disease Risk Factor; Cardiovascular Disease Acute; Cardiovascular Health Status; Cardiovascular Disease (CVD); Cardiovascular Disease Prevention

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: OTHER

Study Groups

AMAB

Individuals assigned male at birth, who will take on feminising gender-affirming care (i.e. cyproterone acetate/leuprorelin/triptorelin + estradiol/estradiol valerate, or estradiol/estradiol valerate alone after undergoing orchiectomy).

Feminizing GAHT

Intervention Type: DRUG

Before gender-affirming surgery, the regimen consists of an antiandrogen (cyproterone acetate or leuprorelin or triptorelin) plus estradiol (estradiol or estradiol valerate), whereas after an oophorectomy, estradiol/estradiol valerate can be administered alone.

AFAB

Individuals assigned male at birth, who will take on masculinizing gender-affirming care (i.e. testosterone, either before and after the hysterectomy with our without oophorectomy, if desired).

Masculinizing GAHT

Intervention Type: DRUG

Before and after gender-affirming surgery, the regimen consists of the administration of testosterone or its esters (testosterone undecanoate, testosterone enanthate)

Interventions

Feminizing GAHT

Before gender-affirming surgery, the regimen consists of an antiandrogen (cyproterone acetate or leuprorelin or triptorelin) plus estradiol (estradiol or estradiol valerate), whereas after an oophorectomy, estradiol/estradiol valerate can be administered alone.

Intervention Type: DRUG

Masculinizing GAHT

Before and after gender-affirming surgery, the regimen consists of the administration of testosterone or its esters (testosterone undecanoate, testosterone enanthate)

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Diagnosis of gender incongruence
• Age 18 years or older at the start of therapy
• Undergoing gender-affirming (replacement or suppressive) hormone therapy with testosterone or with estradiol plus anti-androgens for at least 12 months
• Provision of informed consent for study participation and for the processing of personal and sensitive data

Exclusion Criteria

• Any hormone therapy received before recruitment
• History of cardiovascular events prior to the initiation of hormone therapy

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

IRCCS Azienda Ospedaliero-Universitaria di Bologna

OTHER

Sponsor Role: lead

Responsible Party

Maria Cristina Meriggiola

MD

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola

Bologna, BO, Italy

Site Status: RECRUITING

Countries

Italy

Central Contacts

Maria Cristina Meriggiola, MD, PhD

Role: CONTACT

cristina.meriggiola@unibo.it

+390512144394

Facility Contacts

Maria Cristina Meriggiola, MD, PhD

Role: primary

cristina.meriggiola@unibo.it

+390512144394

Other Identifiers

CV-TGD

Identifier Type: -

Identifier Source: org_study_id